MAPK7 and plasma cell myeloma: A macrocyclic inhibitor of ERK5 (TG02, 3) was reportedin 2013 and found to induce a dose-dependent decrease in cell viabilityon multiple myeloma cell lines.48 Althougha potent ERK5 inhibitor (Kd 43 nM), TG02is however a nonselective inhibitor with low nanomolar inhibitoryactivity against an array of kinases, including cell cycle regulatorsCDK1 and CDK2 and transcriptional regulators CDK7 and CDK9.